Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04144751 · ClinicalTrials.gov registry record
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"
A clinical trial, sponsored by Exact Sciences Corporation.
- Completed
- Registry status
- 23,494
- Enrollment target
NCT04144751: Completed study, sponsored by Exact Sciences Corporation.
NCT04144751 is a clinical trial that has completed, run by Exact Sciences Corporation. The registered enrollment target is 23,494 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04144751 has completed, sponsored by Exact Sciences Corporation.
- COMPLETED
- Registry status
- 23,494 participants
- Enrollment target
Study Summary
The primary objective of this sub-study, 2019-01B, is to collect blood specimens for research use in the development and validation of a blood-based test for colorectal cancer (CRC).
Interventions
- OTHER Blood Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23,494 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2023-03-30 |
What the finished NCT04144751 record still lists
NCT04144751 is an observational study that tracks outcomes without assigning an intervention. Its 23,494 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample Collection is the first listed.
NCT04144751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04144751 about?
NCT04144751 is a clinical study titled "Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"". The primary objective of this sub-study, 2019-01B, is to collect blood specimens for research use in the development and validation of a blood-based test for colorectal cancer (CRC).
What is the current status of trial NCT04144751?
This trial is currently completed. The enrollment target is 23,494 participants. The study started on 2019-11-15. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT04144751?
The interventions under investigation include: Blood Sample Collection (OTHER).
Who is sponsoring clinical trial NCT04144751?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06995898 · 24,000 participants · NA
The Vanguard Study: Testing a New Way to Screen for Cancer
- NCT06486688 · 22,320 participants · NA
Centralized Virtual SBIRT for Pediatric Primary Care
- NCT07413211 · 22,068 participants
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI